Please use this identifier to cite or link to this item:
|Title:||Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial|
|Author:||Sevene, Esperança Júlia Pires|
Banda, Clifford G.
Maculuve, Sónia Amós
Terlouw, Dianne J.
Khoo, Saye H.
Lalloo, David G.
|Abstract:||Background: HIV-infected individuals on antiretroviral therapy (ART) require treatment with artemisinin-based combination therapy (ACT) when infected with malaria. Dihydroartemisinin–piperaquine (DPQ) is recommended for treatment of Plasmodium falciparum malaria, but its efcacy and safety has not been evaluated in HIV-infected individuals on ART, among whom drug–drug interactions are expected. Day-42 adequate clinical and parasitological response (ACPR) and incidence of adverse events were assessed in HIV-infected individuals on non-nucleoside reverse transcriptase inhibitor-based ART (efavirenz and nevirapine) with uncomplicated P. falciparum malaria treated with dihydroartemisinin–piperaquine. Methods: An open label single arm clinical trial was conducted in Malawi (Blantyre and Chikhwawa districts) and Mozambique (Manhiça district) involving patients aged 15–65 years with uncomplicated P. falciparum malaria who were on efavirenz-based or nevirapine-based ART. They received a directly-observed 3-day standard treatment of DPQ and were followed up until day 63 for malaria infection and adverse events. Day-42 PCR-corrected-ACPRs (95% confdence interval [CI]) were calculated for the intention-to-treat (ITT) population. Results: The study enrolled 160 and 61 patients on efavirenz and nevirapine-based ART, with a baseline geometric mean (95% CI) parasite density of 2681 (1964–3661) and 9819 (6606–14,593) parasites/µL, respectively. The day-42 PCR-corrected ACPR (95% CI) was 99.4% (95.6–99.9%) in the efavirenz group and 100% in the nevirapine group. Seri‑ ous adverse events occurred in 5.0% (8/160) and 3.3% (2/61) of the participants in the efavirenz and nevirapine group, respectively, but none were defnitively attributable to DPQ. Cases of prolonged QT interval (>60 ms from baseline) occurred in 31.2% (48/154) and 13.3% (8/60) of the patients on the efavirenz and nevirapine ART groups, respectively. These were not clinically signifcant and resolved spontaneously over time. As this study was not designed to com‑ pare the efcacy and safety of DPQ in the two ART groups, no formal statistical comparisons were made between the two ART groups. Conclusions: DPQ was highly efcacious and safe for the treatment of malaria in HIV-infected patients concurrently taking efavirenz- or nevirapine-based ART, despite known pharmacokinetic interactions between dihydroartemisinin– piperaquine and efavirenz- or nevirapine-based ART regimens|
|Note:||Reproducció del document publicat a: http://dx.doi.org/10.1186/s12936-019-2909-5|
|It is part of:||Malaria Journal, 2019, vol. 18|
|Appears in Collections:||Articles publicats en revistes (ISGlobal)|
This item is licensed under a Creative Commons License